Rhythm Interest Income vs Operating Income Analysis

RYTM Stock

USD 59.22 2.03 3.55%

Rhythm Pharmaceuticals financial indicator trend analysis is much more than just breaking down Rhythm Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Rhythm Pharmaceuticals is a good investment. Please check the relationship between Rhythm Pharmaceuticals Interest Income and its Operating Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

Interest Income vs Operating Income

Interest Income vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Rhythm Pharmaceuticals Interest Income account and Operating Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Rhythm Pharmaceuticals' Interest Income and Operating Income is -0.71. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Operating Income in the same time period over historical financial statements of Rhythm Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Rhythm Pharmaceuticals' Interest Income and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of Rhythm Pharmaceuticals are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Interest Income i.e., Rhythm Pharmaceuticals' Interest Income and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.71

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Operating Income

Operating Income is the amount of profit realized from Rhythm Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Rhythm Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Rhythm Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Rhythm Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.At this time, Rhythm Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 30th of January 2025, Tax Provision is likely to grow to about 681 K, while Enterprise Value Over EBITDA is likely to drop (14.54).

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	1.7M	1.8M	2.1M	1.1M
Interest Income	4.0M	13.2M	15.1M	15.9M

Reconciled Depreciation Interest Income

Rhythm Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Current Deferred Revenue	Other Assets
Total Assets		0.82	0.91	0.88	0.72	-0.74	-0.9	0.75	0.79	0.87	0.81	0.94	0.79	0.42	0.94	0.44	0.9	0.92	0.64	0.88	0.94	0.47	0.94	0.97	0.15	0.79
Other Current Liab	0.82		0.97	0.5	0.38	-0.5	-0.94	0.32	0.54	0.96	0.96	0.65	0.67	0.51	0.66	0.75	0.63	0.94	0.89	0.83	0.67	0.47	0.64	0.92	-0.25	0.97
Total Current Liabilities	0.91	0.97		0.64	0.55	-0.56	-0.96	0.51	0.61	0.96	0.94	0.77	0.73	0.51	0.78	0.67	0.75	0.98	0.84	0.92	0.78	0.48	0.76	0.97	-0.13	0.94
Total Stockholder Equity	0.88	0.5	0.64		0.82	-0.77	-0.68	0.85	0.81	0.61	0.52	0.95	0.71	0.17	0.93	-0.02	0.9	0.69	0.22	0.69	0.94	0.42	0.95	0.77	0.48	0.46
Property Plant And Equipment Net	0.72	0.38	0.55	0.82		-0.74	-0.62	0.79	0.78	0.5	0.37	0.77	0.65	0.28	0.7	-0.04	0.86	0.67	0.17	0.76	0.75	0.36	0.77	0.69	0.46	0.35
Net Debt	-0.74	-0.5	-0.56	-0.77	-0.74		0.7	-0.53	-0.96	-0.63	-0.55	-0.76	-0.64	-0.23	-0.64	-0.12	-0.8	-0.69	-0.29	-0.61	-0.76	-0.49	-0.72	-0.73	-0.17	-0.52
Retained Earnings	-0.9	-0.94	-0.96	-0.68	-0.62	0.7		-0.51	-0.74	-0.95	-0.91	-0.81	-0.79	-0.55	-0.78	-0.63	-0.81	-0.98	-0.8	-0.91	-0.83	-0.52	-0.79	-0.97	0.09	-0.92
Accounts Payable	0.75	0.32	0.51	0.85	0.79	-0.53	-0.51		0.61	0.39	0.28	0.82	0.58	0.3	0.83	0.01	0.8	0.55	0.19	0.66	0.81	0.23	0.85	0.62	0.49	0.25
Cash	0.79	0.54	0.61	0.81	0.78	-0.96	-0.74	0.61		0.66	0.57	0.83	0.71	0.37	0.7	0.19	0.86	0.73	0.36	0.67	0.83	0.35	0.78	0.77	0.21	0.55
Non Current Assets Total	0.87	0.96	0.96	0.61	0.5	-0.63	-0.95	0.39	0.66		0.99	0.74	0.7	0.51	0.73	0.68	0.74	0.96	0.83	0.82	0.76	0.51	0.7	0.94	-0.24	0.98
Non Currrent Assets Other	0.81	0.96	0.94	0.52	0.37	-0.55	-0.91	0.28	0.57	0.99		0.66	0.64	0.49	0.66	0.72	0.65	0.91	0.86	0.75	0.68	0.49	0.62	0.89	-0.34	0.99
Cash And Short Term Investments	0.94	0.65	0.77	0.95	0.77	-0.76	-0.81	0.82	0.83	0.74	0.66		0.82	0.41	0.98	0.24	0.95	0.8	0.45	0.77	1.0	0.47	0.99	0.87	0.28	0.63
Common Stock Total Equity	0.79	0.67	0.73	0.71	0.65	-0.64	-0.79	0.58	0.71	0.7	0.64	0.82		0.5	0.79	0.4	0.79	0.76	0.55	0.73	0.83	0.65	0.81	0.79	0.12	0.63
Common Stock Shares Outstanding	0.42	0.51	0.51	0.17	0.28	-0.23	-0.55	0.3	0.37	0.51	0.49	0.41	0.5		0.38	0.69	0.54	0.51	0.69	0.45	0.44	0.08	0.39	0.49	-0.4	0.55
Short Term Investments	0.94	0.66	0.78	0.93	0.7	-0.64	-0.78	0.83	0.7	0.73	0.66	0.98	0.79	0.38		0.26	0.9	0.79	0.47	0.77	0.98	0.48	0.98	0.85	0.27	0.63
Non Current Liabilities Total	0.44	0.75	0.67	-0.02	-0.04	-0.12	-0.63	0.01	0.19	0.68	0.72	0.24	0.4	0.69	0.26		0.23	0.61	0.96	0.5	0.27	0.21	0.22	0.56	-0.62	0.78
Other Current Assets	0.9	0.63	0.75	0.9	0.86	-0.8	-0.81	0.8	0.86	0.74	0.65	0.95	0.79	0.54	0.9	0.23		0.82	0.44	0.79	0.95	0.44	0.94	0.86	0.22	0.63
Other Stockholder Equity	0.92	0.94	0.98	0.69	0.67	-0.69	-0.98	0.55	0.73	0.96	0.91	0.8	0.76	0.51	0.79	0.61	0.82		0.79	0.95	0.82	0.52	0.79	0.99	-0.07	0.91
Total Liab	0.64	0.89	0.84	0.22	0.17	-0.29	-0.8	0.19	0.36	0.83	0.86	0.45	0.55	0.69	0.47	0.96	0.44	0.79		0.69	0.48	0.33	0.43	0.75	-0.5	0.9
Property Plant And Equipment Gross	0.88	0.83	0.92	0.69	0.76	-0.61	-0.91	0.66	0.67	0.82	0.75	0.77	0.73	0.45	0.77	0.5	0.79	0.95	0.69		0.78	0.47	0.79	0.93	0.11	0.76
Total Current Assets	0.94	0.67	0.78	0.94	0.75	-0.76	-0.83	0.81	0.83	0.76	0.68	1.0	0.83	0.44	0.98	0.27	0.95	0.82	0.48	0.78		0.48	0.99	0.88	0.25	0.65
Common Stock	0.47	0.47	0.48	0.42	0.36	-0.49	-0.52	0.23	0.35	0.51	0.49	0.47	0.65	0.08	0.48	0.21	0.44	0.52	0.33	0.47	0.48		0.49	0.52	-0.09	0.47
Net Tangible Assets	0.94	0.64	0.76	0.95	0.77	-0.72	-0.79	0.85	0.78	0.7	0.62	0.99	0.81	0.39	0.98	0.22	0.94	0.79	0.43	0.79	0.99	0.49		0.86	0.32	0.59
Capital Surpluse	0.97	0.92	0.97	0.77	0.69	-0.73	-0.97	0.62	0.77	0.94	0.89	0.87	0.79	0.49	0.85	0.56	0.86	0.99	0.75	0.93	0.88	0.52	0.86		0.02	0.88
Current Deferred Revenue	0.15	-0.25	-0.13	0.48	0.46	-0.17	0.09	0.49	0.21	-0.24	-0.34	0.28	0.12	-0.4	0.27	-0.62	0.22	-0.07	-0.5	0.11	0.25	-0.09	0.32	0.02		-0.39
Other Assets	0.79	0.97	0.94	0.46	0.35	-0.52	-0.92	0.25	0.55	0.98	0.99	0.63	0.63	0.55	0.63	0.78	0.63	0.91	0.9	0.76	0.65	0.47	0.59	0.88	-0.39

Click cells to compare fundamentals

Rhythm Pharmaceuticals Account Relationship Matchups

Rhythm Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	187.1M	329.5M	382.5M	332.7M	382.7M	401.8M
Other Current Liab	12.0M	29.5M	32.9M	48.3M	55.5M	58.3M
Total Current Liabilities	18.0M	43.4M	39.8M	55.2M	63.5M	66.7M
Total Stockholder Equity	166.5M	284.2M	264.3M	169.8M	195.2M	137.7M
Property Plant And Equipment Net	5.0M	4.3M	3.4M	2.1M	2.4M	2.4M
Net Debt	(97.8M)	(56.7M)	(125.7M)	(58.8M)	(52.9M)	(55.6M)
Retained Earnings	(459.3M)	(528.9M)	(710.1M)	(894.7M)	(805.3M)	(765.0M)
Accounts Payable	4.9M	5.7M	4.8M	4.9M	5.6M	4.4M
Cash	100.9M	59.2M	127.7M	60.1M	69.1M	50.8M
Non Current Assets Total	5.4M	21.1M	28.2M	24.5M	28.1M	29.6M
Cash And Short Term Investments	172.8M	294.9M	333.3M	275.8M	317.2M	169.6M
Common Stock Shares Outstanding	44.1M	49.6M	52.1M	57.7M	66.3M	39.3M
Short Term Investments	71.9M	235.6M	205.6M	215.8M	248.1M	142.5M
Liabilities And Stockholders Equity	187.1M	329.5M	382.5M	332.7M	382.7M	203.9M
Non Current Liabilities Total	2.6M	1.9M	78.4M	107.8M	124.0M	130.1M
Other Current Assets	8.9M	12.4M	11.8M	8.9M	10.3M	5.8M
Other Stockholder Equity	625.8M	813.0M	974.4M	1.1B	1.2B	1.3B
Total Liab	20.5M	45.4M	118.2M	163.0M	187.4M	196.8M
Property Plant And Equipment Gross	5.0M	4.3M	3.4M	6.2M	7.1M	7.5M
Total Current Assets	181.7M	308.4M	354.2M	308.3M	354.5M	178.6M
Accumulated Other Comprehensive Income	49K	(1K)	(92K)	134K	154.1K	161.8K
Net Tangible Assets	281.0M	166.5M	279.5M	256.4M	294.8M	163.0M
Capital Surpluse	606.3M	625.8M	813.0M	974.4M	1.1B	1.2B
Current Deferred Revenue	12.4M	7M	1.4M	1.3M	1.2M	1.1M
Other Assets	403K	2.2M	12.1M	17.0M	19.5M	20.5M
Short Term Debt	1.1M	1.2M	684K	770K	693K	1.0M
Property Plant Equipment	5.7M	3.2M	2.8M	2.2M	2.5M	2.3M
Retained Earnings Total Equity	(325.3M)	(459.3M)	(528.9M)	(710.1M)	(639.1M)	(607.1M)
Net Invested Capital	166.5M	284.2M	264.3M	169.8M	195.2M	244.6M
Net Working Capital	163.7M	265.0M	314.4M	253.1M	291.0M	261.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:

How To Invest In Rhythm

Details

Is Rhythm Stock a good investment?

Details

What is Rhythm Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.32)

Revenue Per Share

1.863

Quarterly Revenue Growth

0.478

Return On Assets

(0.46)

Return On Equity

(1.48)

The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Rhythm Interest Income vs Operating Income Analysis

Interest Income vs Operating Income

Interest Income vs Operating Income Correlation Analysis

Correlation Coefficient

Interest Income

Operating Income

Rhythm Pharmaceuticals fundamental ratios Correlations

Rhythm Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Rhythm Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Other Assets	+ 0.99	Non Currrent Assets Other
Net Tangible Assets	+ 0.99	Cash And Short Term Investments
Capital Surpluse	+ 0.99	Other Stockholder Equity
Net Tangible Assets	+ 0.99	Total Current Assets

Other Stockholder Equity	- 0.98	Retained Earnings
Capital Surpluse	- 0.97	Retained Earnings
Cash	- 0.96	Net Debt
Retained Earnings	- 0.96	Total Current Liabilities
Non Current Assets Total	- 0.95	Retained Earnings
Retained Earnings	- 0.94	Other Current Liab